Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.

DeAngelo DJ, Advani AS, Marks DI, Stelljes M, Liedtke M, Stock W, Gökbuget N, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien S. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.

View in: PubMed

collapse authors with profiles